Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) CEO Peter Greenleaf Sells 195,593 Shares

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) CEO Peter Greenleaf sold 195,593 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.00, for a total transaction of $1,564,744.00. Following the sale, the chief executive officer now directly owns 1,953,892 shares of the company’s stock, valued at approximately $15,631,136. This represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $8.67 on Thursday. The firm’s 50 day moving average is $8.13 and its two-hundred day moving average is $7.86. Aurinia Pharmaceuticals Inc. has a 52 week low of $4.71 and a 52 week high of $10.67. The firm has a market capitalization of $1.24 billion, a P/E ratio of -57.80 and a beta of 1.22. The company has a current ratio of 5.60, a quick ratio of 5.11 and a debt-to-equity ratio of 0.17.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several large investors have recently made changes to their positions in AUPH. GF Fund Management CO. LTD. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Aurinia Pharmaceuticals by 21.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 363,674 shares of the biotechnology company’s stock valued at $3,266,000 after acquiring an additional 65,220 shares during the period. Woodline Partners LP increased its stake in shares of Aurinia Pharmaceuticals by 69.7% during the fourth quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company’s stock valued at $7,628,000 after acquiring an additional 348,983 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter valued at approximately $31,000. Finally, Tang Capital Management LLC increased its stake in shares of Aurinia Pharmaceuticals by 16.6% during the fourth quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after acquiring an additional 1,200,000 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.